NO20084082L - Antistoffer mot insulin-like vekstfaktor 1 reseptorer og deres anvendelse - Google Patents

Antistoffer mot insulin-like vekstfaktor 1 reseptorer og deres anvendelse

Info

Publication number
NO20084082L
NO20084082L NO20084082A NO20084082A NO20084082L NO 20084082 L NO20084082 L NO 20084082L NO 20084082 A NO20084082 A NO 20084082A NO 20084082 A NO20084082 A NO 20084082A NO 20084082 L NO20084082 L NO 20084082L
Authority
NO
Norway
Prior art keywords
insulin
receptors
antibodies
growth factor
amount
Prior art date
Application number
NO20084082A
Other languages
English (en)
Inventor
Ralf Schumacher
Klaus-Peter Kuenkele
Silke Hansen
Dietmar Reusch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084082(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20084082L publication Critical patent/NO20084082L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SAMMENDRAG Et antistoff som bindes til IGF-IR, er av type humant IgG1 eller IgG3 og som er glykosylert med en sukkerkjede på Asn297, nevnte antistoff er karakterisert ved at mengde fukose innen nevnte sukkerkjede er minst 99 % og i tillegg er mengde NGNA 1 % eller mindre og/eller mengde N-terminal alfa-1,3-galaktose 1 % eller mindre, og har forbedrede egenskaper i anti-tumor terapi.
NO20084082A 2006-04-11 2008-09-25 Antistoffer mot insulin-like vekstfaktor 1 reseptorer og deres anvendelse NO20084082L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06007571 2006-04-11
PCT/EP2007/003165 WO2007115814A2 (en) 2006-04-11 2007-04-10 Antibodies against insulin-like growth factor i receptor and uses thereof

Publications (1)

Publication Number Publication Date
NO20084082L true NO20084082L (no) 2008-11-06

Family

ID=36940705

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084082A NO20084082L (no) 2006-04-11 2008-09-25 Antistoffer mot insulin-like vekstfaktor 1 reseptorer og deres anvendelse

Country Status (20)

Country Link
US (1) US20080014203A1 (no)
EP (2) EP2363417A1 (no)
JP (1) JP4718634B2 (no)
KR (2) KR101276513B1 (no)
CN (1) CN101421305B (no)
AR (1) AR060592A1 (no)
AU (1) AU2007236199B2 (no)
BR (1) BRPI0710185B8 (no)
CA (2) CA2647181C (no)
CR (1) CR10301A (no)
EC (1) ECSP088816A (no)
ES (1) ES2403075T3 (no)
IL (1) IL194397A (no)
MX (1) MX2008012950A (no)
NO (1) NO20084082L (no)
NZ (1) NZ571414A (no)
RU (1) RU2541765C2 (no)
UA (1) UA95284C2 (no)
WO (1) WO2007115814A2 (no)
ZA (1) ZA200808597B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
TW200833711A (en) * 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US20100261216A1 (en) 2007-12-21 2010-10-14 Bianca Eser Stability testing of antibodies
NZ592151A (en) 2008-12-12 2012-10-26 Boehringer Ingelheim Int Anti-igf antibodies
WO2010112194A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
AU2010275687A1 (en) 2009-07-24 2012-01-12 F. Hoffmann-La Roche Ag Stirrer system
CA2774953A1 (en) * 2009-10-07 2011-04-14 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (igf) system
ES2622366T3 (es) 2009-10-26 2017-07-06 F. Hoffmann-La Roche Ag Procedimiento para la producción de una inmunoglobulina glucosilada
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
BR112013007237A2 (pt) 2010-11-05 2016-06-14 Hoffmann La Roche ''método para produzir um anticorpo anti-ig-1r''
US20130011394A1 (en) 2011-06-22 2013-01-10 Hoffmann-La Roche Inc. Complexes comprising mhc class i fusion polypeptides and antigen-specific antibodies and methods of use
RU2502798C2 (ru) * 2012-02-22 2013-12-27 Общество с ограниченной ответственностью "Фармако Биотех" КЛЕТОЧНАЯ ЛИНИЯ huFSHIK, СЕКРЕТИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ЧЕЛОВЕЧЕСКИЙ ФСГ
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
JP6475167B2 (ja) 2012-12-21 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
AR120719A1 (es) * 2019-12-10 2022-03-09 Horizon Therapeutics Ireland Designated Activity Company Anticuerpos glicosilados contra el receptor del factor de crecimiento i similar a la insulina y sus usos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5610297A (en) * 1991-12-27 1997-03-11 Georgia Tech Research Corp. Peptides ketoamides
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
ES2568899T3 (es) * 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
ES2383014T3 (es) * 2003-04-02 2012-06-15 F. Hoffmann-La Roche Ag Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
EP1666501A4 (en) * 2003-08-11 2008-12-24 Chugai Pharmaceutical Co Ltd ANTI-HM1.24 ANTIBODIES WITH MODIFIED SUGAR CHAIN
EP1693069B1 (en) * 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Remedy for solid tumor

Also Published As

Publication number Publication date
BRPI0710185A2 (pt) 2011-08-09
NZ571414A (en) 2011-12-22
KR20080113233A (ko) 2008-12-29
AR060592A1 (es) 2008-07-02
BRPI0710185A8 (pt) 2019-01-22
BRPI0710185B1 (pt) 2020-01-14
CN101421305A (zh) 2009-04-29
JP4718634B2 (ja) 2011-07-06
WO2007115814A3 (en) 2008-01-10
CR10301A (es) 2008-10-29
CA2647181C (en) 2020-08-11
ECSP088816A (es) 2008-11-27
EP2007810A2 (en) 2008-12-31
IL194397A (en) 2014-04-30
MX2008012950A (es) 2008-10-15
UA95284C2 (ru) 2011-07-25
KR20120028396A (ko) 2012-03-22
BRPI0710185B8 (pt) 2021-05-25
AU2007236199B2 (en) 2013-07-25
EP2363417A1 (en) 2011-09-07
EP2007810B1 (en) 2013-02-13
US20080014203A1 (en) 2008-01-17
KR101276513B1 (ko) 2013-06-21
RU2541765C2 (ru) 2015-02-20
RU2008144290A (ru) 2010-05-20
WO2007115814A2 (en) 2007-10-18
AU2007236199A1 (en) 2007-10-18
CA3081707A1 (en) 2007-10-18
CN101421305B (zh) 2013-05-15
ZA200808597B (en) 2009-11-25
ES2403075T3 (es) 2013-05-13
JP2009533367A (ja) 2009-09-17
CA2647181A1 (en) 2007-10-18
IL194397A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
NO20084082L (no) Antistoffer mot insulin-like vekstfaktor 1 reseptorer og deres anvendelse
NO20083948L (no) Glykosylerte antistoffer
TW200833712A (en) Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
WO2004087756A3 (en) Antibodies against insulin-like growth factor i receptor and uses thereof
PE20081899A1 (es) Anticuerpos anti-ige
NO20080892L (no) Nye anti-IGF-IR antistoffer og anvendelse derav
NO20073655L (no) Antistoffer mot IL-13 reseptor alfa 1 og anvendelser derav
WO2009048537A3 (en) Humanized antibody
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
DE602004029252D1 (de) Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
RS53752B1 (en) ANTITELO PROTIV ILT7
BRPI0715017A8 (pt) composições e métodos relativos aos anticorpos receptores de glucagon
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
DOP2009000140A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
WO2006099698A3 (en) Novel anti-plgf antibody
EP2463304A3 (en) Monoclonal antibodies that neutralize anthrax toxins
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
WO2006113526A3 (en) Prevention of chlamydia infection using a protective antibody
TH96999B (th) แอนตี้บอดี้ที่ถูกไกลโคซิเลท
TH95354A (th) แอนตี้บอดีต่อโกรท แฟคเตอร์-1 รีเซปเตอร์คล้ายอินซูลิน และการใช้สารนั้น

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: RIVER VISION DEVELOPMENT CORP, US

FC2A Withdrawal, rejection or dismissal of laid open patent application